Using AI to Solve the Misfolded Protein Riddle

Using AI to Solve the Misfolded Protein Riddle

Using AI to Solve the Misfolded Protein Riddle One of the most daunting challenges in drug discovery is finding drugs for proteins that misfold. The primary drug design objective is for a small drug molecules to be able to enter an active site and block an enzyme’s or ion channel’s normal function, inhibiting its action […]

Lilly’s phase 2 Alzheimer’s win marred by missed secondaries, questions about clinical significance

Eli Lilly has shared full data from a phase 2 clinical trial it hailed as showing a “significant slowing of decline” in Alzheimer’s disease patients. The donanemab data are a mixed bag, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s. In January, Lilly […]

Donanemab in Early Alzheimer’s Disease

Abstract BACKGROUND A hallmark of Alzheimer’s disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer’s disease…. … RESULTS A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. […]

BrainStorm to study stem cell treatment in Alzheimer’s patients

TEL AVIV (Reuters) – BrainStorm Cell Therapeutics Inc said on Wednesday it will begin a clinical trial of its experimental stem cell treatment in patients with Alzheimer’s disease. The U.S.-Israeli company is already conducting advanced trials of its treatment called NurOwn in patients with the neurodegenerative disease amyotrophic lateral sclerosis (ALS). MORE…